Faricimab vs Ranibizumab for the Treatment of nAMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
JAMA Ophthalmol 2020 Jul 30;[EPub Ahead of Print], J Sahni, PU Dugel, SS Patel, ME Chittum, B Berger, M Del Valle Rubido, S Sadikhov, P Szczesny, D Schwab, E Nogoceke, R Weikert, S FauserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.